{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Combination+Group&page=29", "query": { "intervention": "Combination Group", "page": 29 }, "page_size": 10 }, "pagination": { "page": 29, "page_size": 10, "total_count": 2795, "total_pages": 280, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Combination+Group&page=30&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Combination+Group&page=28&page_size=10" }, "source": "remote", "last_synced_at": "2026-11-15T01:33:20.377Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT04644120", "title": "Study to Assess Adverse Events and How Intravenous (IV) ABBV-47D11 and IV ABBV-2B04 Given Alone and in Combination Moves Through the Body of Adult Participants With Coronavirus Disease 2019 (COVID-19)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "CoronaVirus Disease-2019 (COVID-19)" ], "interventions": [ { "name": "ABBV-47D11", "type": "DRUG" }, { "name": "Placebo for ABBV-47D11", "type": "DRUG" }, { "name": "ABBV-2B04", "type": "DRUG" }, { "name": "Placebo for ABBV-2B04", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AbbVie", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 25, "start_date": "2020-12-10", "completion_date": "2021-08-24", "has_results": false, "last_update_posted_date": "2021-09-02", "last_synced_at": "2026-11-15T01:33:20.377Z", "location_count": 11, "location_summary": "Glendale, California • Cutler Bay, Florida • Miami, Florida + 8 more", "locations": [ { "city": "Glendale", "state": "California" }, { "city": "Cutler Bay", "state": "Florida" }, { "city": "Miami", "state": "Florida" }, { "city": "West Palm Beach", "state": "Florida" }, { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT04644120" }, { "nct_id": "NCT00000746", "title": "A Phase I, Multicenter, Randomized Trial to Evaluate the Safety and Immunogenicity of a Recombinant Vaccinia-HIV Envelope Vaccine (HIVAC-1e) in Combination With a Panel of Subunit Recombinant HIV Envelope Vaccines", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "HIV Infections" ], "interventions": [ { "name": "rgp120/HIV-1 SF-2", "type": "BIOLOGICAL" }, { "name": "Env 2-3", "type": "BIOLOGICAL" }, { "name": "HIVAC-1e", "type": "BIOLOGICAL" }, { "name": "gp160 Vaccine (MicroGeneSys)", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "60 Years", "sex": "ALL", "summary": "18 Years to 60 Years" }, "enrollment_count": 56, "start_date": null, "completion_date": "1994-07", "has_results": false, "last_update_posted_date": "2021-11-04", "last_synced_at": "2026-11-15T01:33:20.377Z", "location_count": 1, "location_summary": "Pittsburgh, Pennsylvania", "locations": [ { "city": "Pittsburgh", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT00000746" }, { "nct_id": "NCT00330369", "title": "DORADO - Fixed Doses of Darusentan as Compared to Placebo in Resistant Hypertension", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Hypertension" ], "interventions": [ { "name": "Darusentan", "type": "DRUG" }, { "name": "Darusentan Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Gilead Sciences", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "35 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "35 Years to 80 Years" }, "enrollment_count": 352, "start_date": "2006-06", "completion_date": "2009-01", "has_results": false, "last_update_posted_date": "2014-03-18", "last_synced_at": "2026-11-15T01:33:20.377Z", "location_count": 67, "location_summary": "Birmingham, Alabama • Mobile, Alabama • Tucson, Arizona + 62 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Mobile", "state": "Alabama" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Inglewood", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00330369" }, { "nct_id": "NCT00302731", "title": "Bioidentical 'Natural' Hormone Evaluation in Early Menopause", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Menopause" ], "interventions": [ { "name": "Estradiol , estriol , progesterone", "type": "DRUG" }, { "name": "estradiol, progesterone", "type": "DRUG" }, { "name": "estriol, progesterone", "type": "DRUG" }, { "name": "equine estrogens m-progesteroneacetate", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Jeanne Drisko, MD, CNS, FACN", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "40 Years", "maximum_age": "65 Years", "sex": "FEMALE", "summary": "40 Years to 65 Years · Female only" }, "enrollment_count": 21, "start_date": "2006-02", "completion_date": "2014-09", "has_results": true, "last_update_posted_date": "2018-07-06", "last_synced_at": "2026-11-15T01:33:20.377Z", "location_count": 1, "location_summary": "Kansas City, Kansas", "locations": [ { "city": "Kansas City", "state": "Kansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00302731" }, { "nct_id": "NCT07414862", "title": "The Effects of Finger Extensor Training on Climbing Performance Compared With Traditional Flexor Training", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Healthy Adult" ], "interventions": [ { "name": "Traditional Hangboard Protocol", "type": "OTHER" }, { "name": "Extensor Tendon Isometric Training", "type": "OTHER" } ], "intervention_types": [ "OTHER" ], "sponsor": "April Henderson", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 36, "start_date": "2025-11-11", "completion_date": "2026-08-06", "has_results": false, "last_update_posted_date": "2026-06-15", "last_synced_at": "2026-11-15T01:33:20.377Z", "location_count": 1, "location_summary": "Portland, Oregon", "locations": [ { "city": "Portland", "state": "Oregon" } ], "official_url": "https://clinicaltrials.gov/study/NCT07414862" }, { "nct_id": "NCT00594646", "title": "HIV Non Occupational Post-Exposure Prophylaxis (PEP)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "HIV Infections" ], "interventions": [ { "name": "TRUVADA + Raltegravir", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Fenway Community Health", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 100, "start_date": "2008-02", "completion_date": "2010-08", "has_results": true, "last_update_posted_date": "2022-10-25", "last_synced_at": "2026-11-15T01:33:20.377Z", "location_count": 1, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT00594646" }, { "nct_id": "NCT06397651", "title": "A Randomised Controlled Trial to Evaluate the Impact of Complement Theory's Live CoActive Exercise Coaching and Personalized Digital Application on Cancer Survivors' Quality of Life", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Breast Cancer", "Lung Cancer", "Prostate Cancer", "Colorectal Cancer", "Other Cancer" ], "interventions": [ { "name": "Complement Theory's Live CoActive Exercise Coaching and Personalized Digital Application", "type": "BEHAVIORAL" }, { "name": "Digital application with expert guidelines on lifestyle modification", "type": "BEHAVIORAL" } ], "intervention_types": [ "BEHAVIORAL" ], "sponsor": "Complement Theory Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "21 Years", "maximum_age": null, "sex": "ALL", "summary": "21 Years and older" }, "enrollment_count": 146, "start_date": "2024-05-12", "completion_date": "2026-02-28", "has_results": false, "last_update_posted_date": "2025-12-17", "last_synced_at": "2026-11-15T01:33:20.377Z", "location_count": 1, "location_summary": "Dover, Delaware", "locations": [ { "city": "Dover", "state": "Delaware" } ], "official_url": "https://clinicaltrials.gov/study/NCT06397651" }, { "nct_id": "NCT00000703", "title": "Chemotherapy and Azidothymidine, With or Without Radiotherapy, for High Grade Lymphoma in AIDS-Risk Group Members", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Lymphoma, Non-Hodgkin", "HIV Infections" ], "interventions": [ { "name": "Bleomycin sulfate", "type": "DRUG" }, { "name": "Vincristine sulfate", "type": "DRUG" }, { "name": "Doxorubicin hydrochloride", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Allopurinol", "type": "DRUG" }, { "name": "Methotrexate", "type": "DRUG" }, { "name": "Cytarabine", "type": "DRUG" }, { "name": "Leucovorin calcium", "type": "DRUG" }, { "name": "Zidovudine", "type": "DRUG" }, { "name": "Dexamethasone", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "19 Years", "maximum_age": "69 Years", "sex": "ALL", "summary": "19 Years to 69 Years" }, "enrollment_count": 45, "start_date": null, "completion_date": "1990-03", "has_results": false, "last_update_posted_date": "2021-11-03", "last_synced_at": "2026-11-15T01:33:20.377Z", "location_count": 14, "location_summary": "Los Angeles, California • San Francisco, California • Washington D.C., District of Columbia + 6 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "New Orleans", "state": "Louisiana" } ], "official_url": "https://clinicaltrials.gov/study/NCT00000703" }, { "nct_id": "NCT02674854", "title": "Double-masked Study of PG324 Ophthalmic Solution in Patients With Open-angle Glaucoma or Ocular Hypertension", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Open-angle Glaucoma", "Ocular Hypertension" ], "interventions": [ { "name": "PG324 Ophthalmic Solution 0.02%/0.005%", "type": "DRUG" }, { "name": "Netarsudil (AR-13324) ophthalmic solution 0.02%", "type": "DRUG" }, { "name": "Latanoprost ophthalmic solution 0.005%", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Aerie Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "99 Years", "sex": "ALL", "summary": "18 Years to 99 Years" }, "enrollment_count": 750, "start_date": "2016-02", "completion_date": "2017-03", "has_results": true, "last_update_posted_date": "2019-05-21", "last_synced_at": "2026-11-15T01:33:20.377Z", "location_count": 1, "location_summary": "Bedminster, New Jersey", "locations": [ { "city": "Bedminster", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT02674854" }, { "nct_id": "NCT05679388", "title": "A Study of Extending Relugolix Dosing Intervals Through Addition of Itraconazole or Ritonavir in Prostate Cancer Patients", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Prostate Cancer", "Prostate Cancer Metastatic", "Prostate Adenocarcinoma" ], "interventions": [ { "name": "Relugolix Pill", "type": "DRUG" }, { "name": "Ritonavir", "type": "DRUG" }, { "name": "Itraconazole", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Chicago", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 60, "start_date": "2023-02-13", "completion_date": "2024-08-05", "has_results": false, "last_update_posted_date": "2024-09-19", "last_synced_at": "2026-11-15T01:33:20.377Z", "location_count": 1, "location_summary": "Chicago, Illinois", "locations": [ { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT05679388" } ] }